UbiVac LLC

UbiVac LLC, based in Portland, OR, is a clinical-stage immunotherapy cancer target discovery company pioneering innovative treatments that harness dark genome-derived cancer neoantigens for immunotherapy. Their lead agent, DPV-001, combines a unique platform technology with over 300 shared non-mutated cancer antigens, aiming to enhance immune responses in patients with advanced cancers.

Co-founded by cancer immunotherapy expert Dr. Bernard A. Fox, UbiVac focuses on addressing the immune deficiencies in patients with advanced cancer through groundbreaking combination therapies, including their first-in-human trials. The company's research highlights the potential of short-lived non-mutated neoantigens to serve as significant targets for developing universal cancer vaccines, ultimately striving to improve patient outcomes in previously incurable cases.

Generated from the website